4.7 Article

A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy

期刊

CHINESE CHEMICAL LETTERS
卷 33, 期 8, 页码 4089-4095

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cclet.2022.01.071

关键词

Nanovaccine; Graphene Oxide; Adjuvant; Tumor-specific antigen; NLG919

资金

  1. Basic and Applied Basic Research Program of Hainan Province [2019RC209, 820RC646]
  2. National Natural Science Foundation of China [81860037]
  3. China Postdoctoral Science Special Foundations [2015T80488, 2014T70459]

向作者/读者索取更多资源

This study reports a facile approach to prepare a therapeutic cancer nanovaccine based on graphene oxide (GO). The nanovaccine exhibits good biocompatibility, induces an antigen-specific antitumor immune response, and shows a remarkable therapeutic effect against preestablished tumors. Combined with NLG919, it displays a synergistic therapeutic effect by regulating the tumor microenvironment.
With an intensive understanding of the mechanism of immune system, developing a therapeutic tumor vaccine is one of the most perspective strategy of cancer immunotherapy. In this study, we report a facile approach to prepare graphene oxide (GO)-based therapeutic cancer-nanovaccine. The model antigen (ovalbumin, OVA) and adjuvant (CpG ODN), are conjugated with GO-PEI nanosheet through electrostatic interaction. The addition of PEG can improve biocompatibility and prevent nanoparticle aggregation. The prepared GO-based nanovaccine, GO-PEI-OVA-PEG-CpG, exhibits good biocompatibility and low toxicity both in vivo and in vitro. More importantly, it can efficiently induce the maturation of dendritic cells (DCs), the enhancement of antigen cross-presentation ability, and the amplification of cytokine production of immune cells. Impressively, this nanovaccine shows a remarkable therapeutic effect against preestablished B16-OVA-melanoma tumors, which can significantly inhibit tumor growth and prolong the survival time of the OVA-expressed tumor-bearing mice. Moreover, combining GO-PEI-OVA-PEG-CpG with NLG919, an IDO-1 (indoleamine-2,3-dioxygenase) inhibitor which can regulate the tumor microenvironment, displays a synergistic therapeutic effect. These findings indicate the GO-PEI-OVA-PEG-CpG nanovaccine actively induces an antigen-specific antitumor immune response and it combined with NLG919 could achieve better therapeutic outcomes. (C) 2022 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据